Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7788]

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast...

ASCO 2014: Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

ASCO 2014: Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced differentiated thyroid cancer

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced...

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent...

ASCO 2014: LHRH analogue goserelin helps preserve fertility among women undergoing chemotherapy for hormone receptor-negative breast cancer

ASCO 2014: LHRH analogue goserelin helps preserve fertility among women undergoing chemotherapy for hormone...

ASCO 2014: Less frequent zoledronic acid is safe, and has comparable efficacy for women with breast cancer and bone metastases, compared to the standard monthly treatment

ASCO 2014: Less frequent zoledronic acid is safe, and has comparable efficacy for women with breast cancer and...

ASCO 2014: Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

ASCO 2014: Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

New approach for tackling drug resistance in AML

New approach for tackling drug resistance in AML

Guideline update recommends tamoxifen for up to 10 years for women with non-metastatic hormone receptor positive breast cancer

Guideline update recommends tamoxifen for up to 10 years for women with non-metastatic hormone receptor positive...

More from ecancer